Sugi Predict

Sugi Predict / Compounds / SCHEMBL6319683

SCHEMBL6319683

SCHEMBL6319683

CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](CNC(=O)O)Cc1csc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ OPRM1 P35372 2/20 0.44
▸ OPRD1 P41143 2/20 0.44
▸ OPRK1 P41145 2/20 0.44
▸ MMP2 P08253 2/20 0.44
▸ MMP9 P14780 2/20 0.44
▸ MMP8 P22894 2/20 0.44
▸ TP53 P04637 2/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ CTSL P07711 1/20 0.40
▸ CTSS P25774 1/20 0.40
▸ CTSK P43235 1/20 0.40
▸ TAAR1 Q96RJ0 1/20 0.38
▸ MAPT P10636 2/20 0.37
▸ TACR1 P25103 1/20 0.37
▸ PYGL P06737 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ LTA4H P09960 1/20 0.36
▸ CASP1 P29466 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325826 0.89 CTSS (0.51) OPRM1OPRD1OPRK1MMP2MMP9
SCHEMBL6319011 0.85 TAAR1 (0.39) OPRM1OPRD1OPRK1MMP2MMP9
SCHEMBL6317894 0.84 MMP2 (0.48) OPRM1OPRD1OPRK1MMP2MMP9
SCHEMBL6319054 0.84 MMP2 (0.48) OPRM1OPRD1OPRK1MMP2MMP9
SCHEMBL6319686 0.84 MMP2 (0.44) OPRM1OPRD1OPRK1MMP2MMP9
SCHEMBL7063341 0.81 ALDH1A1 (0.44) MMP2MMP9MMP8MAPTLTA4H
SCHEMBL6317169 0.80 CTSL (0.43) OPRM1OPRD1OPRK1MMP2MMP9
SCHEMBL6325830 0.79 CTSL (0.48) OPRM1OPRD1OPRK1MMP2MMP9
SCHEMBL6319923 0.76 TP53 (0.39) OPRM1OPRD1OPRK1MMP2MMP9
SCHEMBL8905226 0.76 MMP9 (0.44) OPRM1OPRD1OPRK1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 — — US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 — — US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 — — US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 — — US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 — — US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 OPRM1 792/4885OPRD1 484/4885OPRK1 552/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR OPRM1 692/4885OPRD1 431/4885OPRK1 541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.